Based on the screening of a novel series of rhodacyanine-based HSP70 inhibitors, Tsai et al. revealed that compound 1 and compound 6 exhibited a high capacity for inhibiting the activity of HSP70′s chaperone and anti-proliferation activities against breast cancer cells [154]. Here, HSPA1A is linked to breast carcinoma.